{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:54:13Z","timestamp":1758257653807,"version":"3.44.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Medullary thyroid carcinoma is a rare thyroid malignancy derived from parafollicular C cells that is frequently driven by activating mutations in the REarranged during Transfection (RET) proto-oncogene. While most actionable RET mutations are located in the extracellular cysteine-rich or intracellular tyrosine kinase domains, mutations in the transmembrane domain are exceedingly rare and their oncogenic significance remains unclear. We report a case of a 59-year-old male with sporadic medullary thyroid carcinoma harboring a rare RET A641R mutation in the transmembrane domain. The patient experienced multiple locoregional recurrences after four surgical resections. While the companion diagnostic test did not identify RET mutations, comprehensive genomic profiling using a next-generation sequencing panel revealed the RET A641R mutation. Following administration of selpercatinib, a selective RET inhibitor, a rapid biochemical response with decreased serum carcinoembryonic antigen and calcitonin levels was observed, and radiological assessment showed partial response. This is the first report demonstrating the clinical efficacy of selpercatinib in a patient with medullary thyroid carcinoma harboring a RET A641R mutation, supporting the oncogenic potential of this rare variant. This case also emphasizes the importance of comprehensive genomic profiling in identifying rare but actionable RET alterations that are undetectable by targeted sequencing companion diagnostic tests. Selpercatinib may represent an effective therapeutic option for patients with medullary thyroid carcinoma driven by uncommon RET mutations, including mutations in the transmembrane domain.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf209","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T15:46:26Z","timestamp":1752162386000},"source":"Crossref","is-referenced-by-count":0,"title":["Sporadic medullary thyroid carcinoma with a rare <i>RET<\/i> transmembrane domain mutation (A641R) that responds to selpercatinib"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5475-9309","authenticated-orcid":false,"given":"Naoki","family":"Fukuda","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]},{"name":"Department of Clinical Cancer Genomics, Hokkaido University Graduate School of Medicine , Sapporo 060-8638,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Toda","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-9997","authenticated-orcid":false,"given":"Tomohiro","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-3708","authenticated-orcid":false,"given":"Ippei","family":"Fukada","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8569-4504","authenticated-orcid":false,"given":"Seiichi","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]},{"name":"Division of Cancer Genomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]},{"name":"Department of Genetic Diagnosis, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tonooka","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erisa","family":"Toda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5310-3423","authenticated-orcid":false,"given":"Jumpei","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4421-0997","authenticated-orcid":false,"given":"Takehiro","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Urasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3721-004X","authenticated-orcid":false,"given":"Kenji","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-451X","authenticated-orcid":false,"given":"Makiko","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Tomomatsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-5800","authenticated-orcid":false,"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-1953","authenticated-orcid":false,"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]},{"name":"Department of Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7091-628X","authenticated-orcid":false,"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo 135-8550,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2025091815425126400_oyaf209-B1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0717","article-title":"New therapeutic approaches to treat medullary thyroid carcinoma","volume":"4","author":"Schlumberger","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab."},{"key":"2025091815425126400_oyaf209-B2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1055-9965.EPI-08-0960","article-title":"Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005","volume":"18","author":"Enewold","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025091815425126400_oyaf209-B3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1586\/14737140.8.4.625","article-title":"RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer","volume":"8","author":"Lodish","year":"2008","journal-title":"Expert Rev Anticancer Ther."},{"key":"2025091815425126400_oyaf209-B4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/jso.20690","article-title":"Current approaches to medullary thyroid carcinoma, sporadic and familial","volume":"94","author":"Fialkowski","year":"2006","journal-title":"J Surg Oncol."},{"key":"2025091815425126400_oyaf209-B5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"key":"2025091815425126400_oyaf209-B6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"2025091815425126400_oyaf209-B7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.91.4.1579","article-title":"Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B","volume":"91","author":"Carlson","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025091815425126400_oyaf209-B8","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2025091815425126400_oyaf209-B9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ncponc0610","article-title":"Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy","volume":"3","author":"Drosten","year":"2006","journal-title":"Nat Clin Pract Oncol."},{"key":"2025091815425126400_oyaf209-B10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrendo.2011.139","article-title":"Management of medullary thyroid carcinoma and MEN2 syndromes in childhood","volume":"7","author":"Waguespack","year":"2011","journal-title":"Nat Rev Endocrinol."},{"key":"2025091815425126400_oyaf209-B11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"2025091815425126400_oyaf209-B12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2025091815425126400_oyaf209-B13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2025091815425126400_oyaf209-B14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2025091815425126400_oyaf209-B15","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.18632\/oncotarget.23986","article-title":"RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases","volume":"9","author":"Romei","year":"2018","journal-title":"Oncotarget"},{"key":"2025091815425126400_oyaf209-B16","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1158\/1078-0432.CCR-09-0786","article-title":"Targeting RET receptor tyrosine kinase activation in cancer","volume":"16","author":"Phay","year":"2010","journal-title":"Clin Cancer Res."},{"key":"2025091815425126400_oyaf209-B17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1530\/EJE-07-0817","article-title":"Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma","volume":"158","author":"Colombo-Benkmann","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2025091815425126400_oyaf209-B18","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1038\/sj.onc.1209698","article-title":"Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations","volume":"25","author":"Kjaer","year":"2006","journal-title":"Oncogene"},{"key":"2025091815425126400_oyaf209-B19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00109-004-0604-6","article-title":"Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome","volume":"83","author":"Poturnajova","year":"2005","journal-title":"J Mol Med (Berl)"},{"key":"2025091815425126400_oyaf209-B20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4183\/aeb.2015.189","article-title":"A new germline Ala641Thr variant in the transmembrane domain of the ret gene associated with medullary thyroid cancer","volume":"11","author":"Kim","year":"2015","journal-title":"Acta Endocrinol (Buchar)"},{"key":"2025091815425126400_oyaf209-B21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s001090100250","article-title":"Three novel mutations in the RET proto-oncogene","volume":"79","author":"Kalinin","year":"2001","journal-title":"J Mol Med (Berl)"},{"author":"Hadoux","key":"2025091815425126400_oyaf209-B22"},{"key":"2025091815425126400_oyaf209-B23","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1210\/jc.2010-1921","article-title":"High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas","volume":"96","author":"Moura","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2025091815425126400_oyaf209-B24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/thy.2012.0207","article-title":"Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series","volume":"23","author":"Ciampi","year":"2013","journal-title":"Thyroid"},{"key":"2025091815425126400_oyaf209-B25","doi-asserted-by":"crossref","first-page":"bvae048","DOI":"10.1210\/jendso\/bvae048","article-title":"Next-generation sequencing in sporadic medullary thyroid cancer patients: mutation profile and disease aggressiveness","volume":"8","author":"Shirali","year":"2024","journal-title":"J Endocr Soc"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf209\/63724078\/oyaf209.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf209\/63724078\/oyaf209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf209\/63724078\/oyaf209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:43:02Z","timestamp":1758224582000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf209\/8196221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf209","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,10]]},"article-number":"oyaf209"}}